Knight Therapeutics Inc KHTRF

Primary Symbol: T.GUD

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Bought back 196,000 shares

<< Previous

Bullboard Posts

Next >>

Comment by gudisgoodon Jul 08, 2022 5:32am

145 Views

Post# 34810364

RE:Bought back 196,000 shares

MrMugsy wrote:

Filed 2022-07-07 14:09

Tx date 2022-06-30 $GUD
Knight Therapeutics Inc. Knight Therapeutics Inc.
1 - Issuer

Direct Ownership

Common Shares
38 - Redemption, retraction, cancellation, repurchase
-195,970 vol

Filed 2022-07-07 14:09 Tx date 2022-06-30	$GUD Knight Therapeutics Inc.	Knight Therapeutics Inc. 1 - Issuer Direct Ownership	Common Shares 38 - Redemption, retraction, cancellation, repurchase	-195,970 vol

Interesting, the buybacks have effectively stopped? I hope that's a sign of there being an attractive acquisition target. Perhaps they've found even better uses for the money. :)

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China